论文部分内容阅读
目的为探索日本血吸虫（中国大陆株）22．6kDa抗原（Sj22．6）编码基因用作核酸疫苗的可行性。方法以PCR法对此编码基因改造后将其亚克隆入真核表达载体质粒PCMV－β并转化入大肠杆菌JM109进行大量扩增。将提纯的PCMV／Sj22．6基因重组质粒在体外转化C2C12真核细胞。结果免疫组化试验证明，该重组质粒能够在体外培养的C2C12细胞中表达Sj22.6抗原。结论表明该重组质粒有用作真核疫苗的可能性。
Objective To explore the feasibility of using the gene encoding 22.6kDa antigen (Sj22.6) of Schistosoma japonicum (Chinese mainland strain) as a nucleic acid vaccine. Methods The gene was subcloned into the eukaryotic expression plasmid PCMV-β by PCR and transformed into E. coli JM109 for amplification. The purified PCMV / Sj22.6 gene recombinant plasmid was transformed into C2C12 eukaryotic cells in vitro. Results Immunohistochemistry showed that the recombinant plasmid could express Sj22.6 antigen in C2C12 cells cultured in vitro. The conclusion shows that the recombinant plasmid has the potential to be used as a eukaryotic vaccine.